Back to GetFilings.com

SECURITIES & EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Haber, Inc.

1009 Avenue C, Suite. #6
Bayonne, NJ 07002

(Address of principal executive offices)

(201) 243-0011

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the proceeding 12 months and (2) has been subject to such filing requirements for the past 90 days.

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the close of the period covered by this report: 96,354,513 shares of Common Stock, $.01 par value

PART I - FINANCIAL INFORMATION

HABER, INC.

See Notes to Financial Statements

HABER, INC.

A DEVELOPMENT STAGE ENTERPRISE
BALANCE SHEET
(UNAUDITED)

LIABILITIES AND STOCKHOLDERS' DEFICIT

See Notes to Financial Statements

HABER, INC.

A DEVELOPMENT STAGE ENTERPRISE
STATEMENT OF OPERATIONS
(UNAUDITED)

See Notes to Financial Statements

HABER, INC.

A DEVELOPMENT STAGE ENTERPRISE
STATEMENT OF OPERATIONS
(UNAUDITED)

See Notes to Financial Statements

HABER, INC.

A DEVELOPMENT STAGE ENTERPRISE
STATEMENT OF CASH FLOWS
(UNAUDITED)

See Notes to Financial Statements

HABER, INC.

A DEVELOPMENT STAGE ENTERPRISE
STATEMENTS OF CASH FLOWS
(UNAUDITED)

See Notes to Financial Statements

HABER, INC.

A DEVELOPMENT STAGE ENTERPRISE
NOTES TO FINANCIAL STATEMENTS
FEBRUARY 28, 2002
(UNAUDITED)

NOTE 1 - REGARDING FINANCIAL STATEMENTS:

The financial information herein submitted is unaudited. However, in the opinion of management, such information reflects all adjustments (consisting only of normal occurring accruals) necessary for a fair statement of the results of operations for the periods being presented. Additionally, it should be noted that the accompanying condensed financial statements do not purport to be a complete disclosure in conformity with generally accepted accounting principles. These condensed statements should be read in conjunction with the Company's financial statements for the fiscal year ended May 31, 2001 and the Form 10-K dated June 20, 2002.

NOTE 2 - DUE FROM/TO RELATED PARTIES:

Receivables and Payables have been generated by transactions with related parties, which are detailed as follows:

NOTE 3 - CAPITAL STOCK:

During the six months ended February 28, 2002 the Company issued 5,548,213 shares of common stock, par value $.01 per share, for an aggregate consideration of $13,920 in cash and $176,688 in services received by the Company

Also during the period June 1, 2001 to February 28, 2002, the Company issued 1,500,000 common stock warrants at a cost to the Company of $26,250 in services performed by the warrant grantees.

Finally, during the nine months ended February 28, 2002, Haber, Inc granted 1,912,496 common stock warrants to various common stock shareholders based on certain previous Haber, Inc. common stock purchases.

NOTE 4 - OTHER MATTER:

The financial statements reflect a net loss of $(288,397) for the six months ended February 28, 2002 with accumulated (deficits) of $(23,341,662) as of the date.

It is highly likely that the Company will continue to sustain losses for the foreseeable future. Accordingly, the Company will continue to be dependent upon equity financing, the sale of its assets, or loans from officers and directors for operating funds.

PART I

Item 1.     Management's Discussion and Analysis of Financial Condition and Results of Operations

Results of Operations:

The Registrant's controls the proprietary operational features and key science insights for the technology called ElectroMolecular Propulsion ("EMP"), which it believes has broad application in the chemical, biomedical and electronic fields. EMP is a fundamental electrokinetic technology invented by Norman Haber. Essentially, EMP is a method of transporting and controlling a broad variety of molecules by means of an electrical field. EMP technology is uqnique and distinguishable from conventional electrophoresis. This ability, enhanced by other characteristics of the technology, indicates that EMP has a range of applications in chemical analytical instrumentation, extraction, purifications, control of chemical reactions electronic, and other uses.

More than 150 application protocols have been completed using the EMP instrument for use with dyes, proteins, etc. Such pre-figured protocols are an important user-friendly feature for the sale and use of the EMP instrument in niche markets. It enables the user to program the EMP instrument for their particular application for chemistry analysis, and quality control.

The Registrant will continue to effect reductions in its operating expenses while conforming continuing operations with the limited amount of working capital available. This policy will continue until revenue from sales or adequate refinancing enables otherwise. The Company is currently occupying office space in Bayonne, NJ. It is anticipated that the Registrant will remain at the current site in 2003. The Company currently leases laboratory, and storage space in Fort Pierce, FL

The Registrant has continued its development activities regarding EMP applications for niche market in analytical instrumentation. Regarding applications for the dye industry, Registrant has since 1997 joined the American Association of Textile Chemists and Colorists (AATCC), and has attended several annual AATCC meetings and exhibitions in Louisville, KY. Other application projects and technical publications describing EMP instrumentation application also are being considered.

The Registrant has undertaken steps toward the re-engineering of its EMP 15K model, with the view of producing an upgraded digitized and computer compatible instrument. These units can be subcontracted through instrument manufacturers.

Dr. Henry Rosenberg, Ph. D. (chemistry) has since 1996 been associated with the Company and has become conversant with both the EMP technology, and the proprietary "Haber Gold Process". Dr. Rosenberg has had extensive sales and marketing experience with scientific instrumentation and is also assisting the Company in this capacity.

Revenues:

The Company did not have any revenues for the nine months ended February 28, 2002, and reported a net loss for the quarter of $(288,397).

General and Administrative Expenses:

General and administrative expenses totaled $159,807 for the nine months ended February 28, 2002. This is a decrease of $123,858 compared to the nine minths ended February 28, 2001.

Research and Development Expenses:

Research and development expenses incurred totaled $128,590 for the nine months ended February 28, 2002. Research and development expenditures totaled $-0- for the comparable period in year ended February 28, 2001

Liquidity and Capital Resources:

The Registrant's liquidity and working capital, summarized in the following table, changed during the nine months ended February 28, 2002, as follows:

The Registrant's deficit working capital and liquidity position at February 28, 2002 must be supplemented in order to meet the demands upon its working capital and the necessity for additional funds to finance development and commercialization of projects built around the Registrant's technologies.

The registrant will continue to seek additional funds and there is no assurance that the Company will be able to sustain its financial needs. The Registrant is endeavoring to reorganize its technological position in order to attract dealers for its instruments both abroad and in the U.S. In addition, it is continuing in search of alternative financing directions, but continues to rely heavily upon its Directors and existing shareholders for financial support.

PART II - OTHER INFORMATION

Item 1.    Other Information

None.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.